ישראל - עברית - Ministry of Health

astrazeneca (israel) ltd - esomeprazole - טבליה - esomeprazole 20 mg - esomeprazole - esomeprazole - nexium tablets are indicated for: gastroesophageal reflux disease (gerd): - treatment of erosive reflux esophagitis - long-term management of patients with healed esophagitis to prevent relapse - symptomatic treatment of gastroesophageal reflux disease (gerd). in combination with an appropriate antibacterial therapeutic regimen for the eradication of helicobacter pylori and: - healing of helicobacter pylori associated duodenal ulcer and - prevention of relapse of peptic ulcers in patients with helicobacter pylory associated ulcers. - healing of gastric ulcers associated with nsaid therapy. - prevention of gastric and duodenal ulcers associated with nsaid therapy in patients at risk.prolonged treatment after i.v induced prevention of rebleeding of peptic ulcers.

ישראל - עברית - Ministry of Health

astrazeneca (israel) ltd - esomeprazole - טבליה - esomeprazole 40 mg - esomeprazole - esomeprazole - nexium tablets are indicated for: gastroesophageal reflux disease (gerd): - treatment of erosive reflux esophagitis - long-term management of patients with healed esophagitis to prevent relapse - symptomatic treatment of gastroesophageal reflux disease (gerd). in combination with an appropriate antibacterial therapeutic regimen for the eradication of helicobacter pylori and: - healing of helicobacter pylori associated duodenal ulcer and - prevention of relapse of peptic ulcers in patients with helicobacter pylory associated ulcers. - healing of gastric ulcers associated with nsaid therapy. - prevention of gastric and duodenal ulcers associated with nsaid therapy in patients at risk.prolonged treatment after i.v induced prevention of rebleeding of peptic ulcers.

ישראל - עברית - Ministry of Health

astrazeneca (israel) ltd - ticagrelor - טבליות מצופות פילם - ticagrelor 90 mg - ticagrelor - ticagrelor - brilinta, co-administered with acetylsalicylic acid (asa), is indicated for the prevention of atherothrombotic events in adult patients with acute coronary syndromes (unstable angina, non st elevation myocardial infarction [nstemi] or st elevation myocardial infarction [stemi]); including patients managed medically, and those who are managed with percutaneous coronary intervention (pci) or coronary artery by-pass grafting (cabg).

ישראל - עברית - Ministry of Health

astrazeneca (israel) ltd - budesonide micronized; formoterol fumarate - אבקה לשאיפה - budesonide micronized 80 mcg/dose; formoterol fumarate 4.5 mcg/dose - formoterol and budesonide - formoterol and other drugs for obstructive airway diseases - symbicort turbuhaler is indicated in the regular treatment of asthma where use of a combination (inhaled corticosteroid and long acting beta-agonist) is appropriate: - patients not adequaterly controlled with inhaled corticosteroids and " as needed" inhaled short acting beta2- agonists. - or patients already adequately controlled on both inhaled corticosteroids and long acting beta2- agonists. note: symbicort turbuhaler 80/4.5 mcg/dose is not appropriate in patients with severe asthma.

ישראל - עברית - Ministry of Health

astrazeneca (israel) ltd - budesonide micronized; formoterol fumarate - אבקה לשאיפה - budesonide micronized 160 mcg/dose; formoterol fumarate 4.5 mcg/dose - formoterol and budesonide - formoterol and other drugs for obstructive airway diseases - asthma symbicort turbuhaler is indicated in the regular treatment of asthma in adults and adolescents age 12 years and above where use of a combination (inhaled corticosteroid and long acting beta-agonist) is appropriate: - patients not adequately controlled with inhaled corticosteroids and " as needed" inhaled short acting beta2- agonists. or - patients already adequately controlled on both inhaled corticosteroids and long acting beta2- agonists. copd symptomatic treatment of patients with severe copd (fev1 < 50 % predicted normal) and a history of repeated exacerbations who have significant symptoms despite regular therapy with long-acting bronchodilators.

ישראל - עברית - Ministry of Health

astrazeneca (israel) ltd - budesonide micronized; formoterol fumarate - אבקה לשאיפה - budesonide micronized 320 mcg/dose; formoterol fumarate 9 mcg/dose - formoterol and budesonide - formoterol and other drugs for obstructive airway diseases - symbicort turbuhaler is indicated in the regular treatment of asthma in adults and adolescents (over the age of 12 years) where use of a combination (inhaled corticosteroid and long acting beta-agonist) is appropriate: - patients not adequaterly controlled with inhaled corticosteroids and " as needed" inhaled short acting beta2- agonists. - or patients already adequately controlled on both inhaled corticosteroids and long acting beta2- agonists. copd symptomatic treatment of patients with severe copd (fev1 < 50 % predicted normal) and a history of repeated exacerbations who have significant symptoms despite regular therapy with long-acting bronchodilators.

ישראל - עברית - Ministry of Health

astrazeneca (israel) ltd - budesonide - אבקה לשאיפה - budesonide 200 mcg/dose - budesonide - budesonide - bronchial asthma.

ישראל - עברית - Ministry of Health

astrazeneca (israel) ltd - budesonide - אבקה לשאיפה - budesonide 100 mcg/dose - budesonide - budesonide - bronchial asthma.

ישראל - עברית - Ministry of Health

astrazeneca (israel) ltd - budesonide - תרחיף לשאיפה - budesonide 0.25 mg/ml - budesonide - budesonide - bronchial asthma, especially in cases where other therapy is insufficient or unsuitable.

ישראל - עברית - Ministry of Health

astrazeneca (israel) ltd - budesonide - תרחיף לשאיפה - budesonide 0.5 mg/ml - budesonide - budesonide - bronchial asthma, especially in cases where other therapy is insufficient or unsuitable.